Patent · US Active

Modular antigen transportation molecules and uses therof

US9920101B2 · kind B2 · utility

0Cited by

3References

33Claims

0Family size

Assignee

BOEHRINGER INGELHEIM VETMEDICA GMBH · DE

Inventors

Horst Rose · Burgdorf, DE
Dania Birte REICHE · Bingen, DE
Harald Tammen · Hannover, DE

Key dates

Filing date	Mar 27, 2015
Grant date	Mar 20, 2018
Priority date	—
Expiry date	Mar 27, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/40
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.